Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Boston Scientific Gives Up On Lotus Edge TAVR

Nov 17 2020

• By Reed Miller

Hand holding scissors to cut banknotes — • Source: shutterstock.com

Related Content

Boston Scientific Becomes Third US TAVR Competitor With Lotus Edge Approval

Apr 24 2019

Symetis TAVR Buy Not About Throwing Shade On Lotus, BSX Insists

Mar 30 2017

Boston Scientific's TAVR Pipeline Delayed; FDA Approval Of Acurate neo2 Set For 2024

Oct 20 2020

Boston Scientific Exceeds Wall Street’s Expectations In Q3

Oct 29 2020

Boston Scientific Expects Up To $40M Impact In Q1 From Coronavirus Outbreak; 10%-12% Revenue Increase For 2020

Feb 05 2020

Related Companies

Boston Scientific Corporation

Medtronic plc

Edwards Lifesciences Corp.

Additional Topics

Business Strategies Commercial Clinical Trials Companies Research & Development Cardiovascular Cardiology Medical Device

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window